This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Clark, W. M. Articles by Hamilton, S. Search for Related Content PubMed PubMed Citation Articles by Clark, W. M. Articles by Hamilton, S. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Stroke Related Collections Thrombolysis Acute Cerebral Infarction Emergency treatment of Stroke

(Stroke. 2000;31:811.)
© 2000 American Heart Association, Inc.

Original Contributions

The rtPA (Alteplase) 0- to 6-Hour Acute Stroke Trial, Part A (A0276g)

Results of a Double-Blind, Placebo-Controlled, Multicenter Study

Wayne M. Clark, MD; Gregory W. Albers, MD; Kenneth P. Madden, MD, PhD; Scott Hamilton, PhD for the Thrombolytic Therapy in Acute Ischemic Stroke Study Investigators

From the Oregon Stroke Center, Portland, Ore (W.M.C.); Stanford Stroke Center, Palo Alto, Calif (G.W.A.); Marshfield Clinic, Marshfield, Wis (K.P.M.); and Genentech, Inc, South San Francisco, Calif (S.H.).

Correspondence to Wayne M. Clark, MD, Oregon Stroke Center, UHS 44, Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd, Portland, OR 97201. E-mail clarkw{at}ohsu.edu

Background and Purpose—The Thrombolytic Therapy in Acute Ischemic Stroke Study, which started in August of 1991, was designed to assess the efficacy and safety of intravenous rtPA (alteplase) in patients with acute (0 to 6 hours) ischemic stroke. In October 1993 enrollment was halted because of Safety Committee (DMSB) concerns. In December 1993 the time window was changed to 0 to 5 hours, and it was decided to restart enrollment as a separate study (part B). We report here the results of the original study (part A), focusing on evaluating the safety and efficacy of rtPA given between 0 and 6 hours after stroke onset.

Methods—This investigation was a phase II, placebo-controlled, double-blind, randomized study utilizing 0.9 mg/kg IV rtPA or placebo over 1 hour, which was conducted at university and community sites in North America. Except for time to treatment, enrollment criteria were very similar to those of the NINDS rtPA stroke study. Primary efficacy end points were the number of patients with a decrease of 4 or more points on the National Institutes of Health Stroke Scale (NIHSS) at 24 hours and day 30, along with infarct volume at day 30. Secondary end points included mortality and functional recoveries on the Barthel Index and Modified Rankin scale at days 30 and 90.

Results—A total of 142 patients were enrolled at 42 sites in North America, including 22 <3 hours (15%) and 46 between 5 and 6 hours (32%). The groups were well matched on baseline characteristics, including NIHSS (mean of 13 for both). For the primary end points, a higher percentage of rtPA patients had a 4-point improvement at 24 hours (placebo 21%, rtPA 40%; P=0.02); however, this early effect was reversed by 30 days, with more placebo patients having a 4-point improvement (75%) than patients treated with rtPA (60%, P=0.05). Treatment with rtPA significantly increased the rate of symptomatic intracerebral hemorrhage within 10 days (11% versus 0%, P<0.01) and mortality at 90 days (23% versus 7%, P<0.01).

Conclusions—This study found no significant rtPA benefit on any of the planned efficacy end points at 30 and 90 days in patients treated between 0 and 6 hours after stroke onset. These negative results apply to patients treated after 3 hours, because only 15% of the patients were enrolled before 3 hours. The risk of symptomatic intracerebral hemorrhage was increased with rtPA treatment, particularly in patients treated between 5 and 6 hours after onset. These results do not support the use of intravenous rtPA for stroke treatment >3 hours after onset.

Key Words: stroke • therapy • thrombolysis • tissue plasminogen activator

This article has been cited by other articles:

				K.R. Lees, G.A. Ford, K.W. Muir, N. Ahmed, A.G. Dyker, S. Atula, L. Kalra, E.A. Warburton, J.-C. Baron, D.F. Jenkinson, et al. Thrombolytic therapy for acute stroke in the United Kingdom: experience from the safe implementation of thrombolysis in stroke (SITS) register QJM, August 11, 2008; (2008) hcn102v1. [Abstract] [Full Text] [PDF]

				V. Hertzberg, T. Ingall, W. O'Fallon, K. Asplund, L. Goldfrank, T. Louis, and T. Christianson Methods and processes for the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial Clinical Trials, August 1, 2008; 5(4): 308 - 315. [Abstract] [PDF]

				J Kendall Thrombolysis for acute ischaemic stroke: a new challenge for emergency medicine Emerg. Med. J., August 1, 2008; 25(8): 471 - 475. [Abstract] [Full Text] [PDF]

				G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 630S - 669S. [Abstract] [Full Text] [PDF]

				J. De Keyser, Z. Gdovinova, M. Uyttenboogaart, P. C. Vroomen, and G. J. Luijckx Intravenous Alteplase for Stroke: Beyond the Guidelines and in Particular Clinical Situations Stroke, September 1, 2007; 38(9): 2612 - 2618. [Abstract] [Full Text] [PDF]

				The Optimising Analysis of Stroke Trials (OAST) Co Can We Improve the Statistical Analysis of Stroke Trials?: Statistical Reanalysis of Functional Outcomes in Stroke Trials * OAST Supplemental Appendix I: Statistical Tests Compared (see Table I) * OAST Supplemental Appendix II: Supplementary Analyses * OAST Supplemental Appendix III: Trial Data (see Tables II and III) * OAST Supplemental Appendix IV: Results (see Table IV) Stroke, June 1, 2007; 38(6): 1911 - 1915. [Abstract] [Full Text] [PDF]

				P. Khatri, L. R. Wechsler, and J. P. Broderick Intracranial Hemorrhage Associated With Revascularization Therapies Stroke, February 1, 2007; 38(2): 431 - 440. [Abstract] [Full Text] [PDF]

				J. A. Sattin, S. E. Olson, L. Liu, R. Raman, and P. D. Lyden An Expedited Code Stroke Protocol Is Feasible and Safe Stroke, December 1, 2006; 37(12): 2935 - 2939. [Abstract] [Full Text] [PDF]

				The IMS Study Investigators Hemorrhage in the Interventional Management of Stroke Study Stroke, March 1, 2006; 37(3): 847 - 851. [Abstract] [Full Text] [PDF]

				G. Thomalla, C. Schwark, J. Sobesky, E. Bluhmki, J. B. Fiebach, J. Fiehler, O. Zaro Weber, T. Kucinski, E. Juettler, P. A. Ringleb, et al. Outcome and Symptomatic Bleeding Complications of Intravenous Thrombolysis Within 6 Hours in MRI-Selected Stroke Patients: Comparison of a German Multicenter Study With the Pooled Data of ATLANTIS, ECASS, and NINDS tPA Trials Stroke, March 1, 2006; 37(3): 852 - 858. [Abstract] [Full Text] [PDF]

				J. Berrouschot, J. Rother, J. Glahn, T. Kucinski, J. Fiehler, and G. Thomalla Outcome and Severe Hemorrhagic Complications of Intravenous Thrombolysis With Tissue Plasminogen Activator in Very Old (>=80 Years) Stroke Patients Stroke, November 1, 2005; 36(11): 2421 - 2425. [Abstract] [Full Text] [PDF]

				D. M. Kent, M. D. Hill, R. Ruthazer, S. B. Coutts, A. M. Demchuk, I. Dzialowski, O. Wunderlich, and R. von Kummer "Clinical-CT Mismatch" and the Response to Systemic Thrombolytic Therapy in Acute Ischemic Stroke Stroke, August 1, 2005; 36(8): 1695 - 1699. [Abstract] [Full Text] [PDF]

				A. Ergin and N. Ergin Is Thrombolytic Therapy Associated With Increased Mortality?: Meta-analysis of Randomized Controlled Trials Arch Neurol, March 1, 2005; 62(3): 362 - 366. [Abstract] [Full Text] [PDF]

				D. M. Kent, L. L. Price, P. Ringleb, M. D. Hill, and H. P. Selker Sex-Based Differences in Response to Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke: A Pooled Analysis of Randomized Clinical Trials Stroke, January 1, 2005; 36(1): 62 - 65. [Abstract] [Full Text] [PDF]

				Y. Pierre Gobin, S. Starkman, G. R. Duckwiler, T. Grobelny, C. S. Kidwell, R. Jahan, J. Pile-Spellman, A. Segal, F. Vinuela, and J. L. Saver MERCI 1: A Phase 1 Study of Mechanical Embolus Removal in Cerebral Ischemia Stroke, December 1, 2004; 35(12): 2848 - 2854. [Abstract] [Full Text] [PDF]

				J. W. Simpkins, S.-H. Yang, R. Liu, E. Perez, Z. Y. Cai, D. F. Covey, and P. S. Green Estrogen-Like Compounds for Ischemic Neuroprotection Stroke, November 1, 2004; 35(11_suppl_1): 2648 - 2651. [Abstract] [Full Text] [PDF]

				G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 483S - 512S. [Abstract] [Full Text] [PDF]

				C. S. Weaver, J. Leonardi-Bee, F. J. Bath-Hextall, and P. M.W. Bath Sample Size Calculations in Acute Stroke Trials: A Systematic Review of Their Reporting, Characteristics, and Relationship With Outcome Stroke, May 1, 2004; 35(5): 1216 - 1224. [Abstract] [Full Text] [PDF]

				D. M. Kent, J. Hinchey, L. L. Price, S. R. Levine, and H. P. Selker In Acute Ischemic Stroke, Are Asymptomatic Intracranial Hemorrhages Clinically Innocuous? Stroke, May 1, 2004; 35(5): 1141 - 1146. [Abstract] [Full Text] [PDF]

				R. T. Higashida and A. J. Furlan Trial Design and Reporting Standards for Intra-Arterial Cerebral Thrombolysis for Acute Ischemic Stroke Stroke, August 1, 2003; 34 (8): e109 - e137. [Abstract] [Full Text] [PDF]

				J.M. Wardlaw, P.A.G. Sandercock, and E. Berge Thrombolytic Therapy With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke: Where Do We Go From Here? A Cumulative Meta-Analysis Stroke, June 1, 2003; 34(6): 1437 - 1442. [Abstract] [Full Text] [PDF]

				D. Saur, T. Kucinski, U. Grzyska, B. Eckert, C. Eggers, W. Niesen, V. Schoder, H. Zeumer, C. Weiller, and J. Rother Sensitivity and Interrater Agreement of CT and Diffusion-Weighted MR Imaging in Hyperacute Stroke AJNR Am. J. Neuroradiol., May 1, 2003; 24(5): 878 - 885. [Abstract] [Full Text] [PDF]

				H. P. Adams Jr, R. J. Adams, T. Brott, G. J. del Zoppo, A. Furlan, L. B. Goldstein, R. L. Grubb, R. Higashida, C. Kidwell, T. G. Kwiatkowski, et al. Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association Stroke, April 1, 2003; 34(4): 1056 - 1083. [Full Text] [PDF]

				B. R. Mahon, G. M. Nesbit, S. L. Barnwell, W. Clark, T. R. Marotta, A. Weill, P. A. Teal, and A. I. Qureshi North American Clinical Experience with the EKOS MicroLysUS Infusion Catheter for the Treatment of Embolic Stroke AJNR Am. J. Neuroradiol., March 1, 2003; 24(3): 534 - 538. [Abstract] [Full Text] [PDF]

				W. F. Baker Jr Thrombolytic Therapy Clinical and Applied Thrombosis/Hemostasis, October 1, 2002; 8(4): 291 - 314. [PDF]

				J. P. Broderick and W. Hacke Treatment of Acute Ischemic Stroke: Part I: Recanalization Strategies Circulation, September 17, 2002; 106(12): 1563 - 1569. [Full Text] [PDF]

				C. A. Molina, J. Alvarez-Sabin, J. Montaner, S. Abilleira, J. F. Arenillas, P. Coscojuela, F. Romero, and A. Codina Thrombolysis-Related Hemorrhagic Infarction: A Marker of Early Reperfusion, Reduced Infarct Size, and Improved Outcome in Patients With Proximal Middle Cerebral Artery Occlusion Stroke, June 1, 2002; 33(6): 1551 - 1556. [Abstract] [Full Text] [PDF]

				J. Lenzer, C. Warlow, J. L Saver, C. S Kidwell, and S. Starkman Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign * Commentary: Who pays the guideline writers? * Commentary: Thrombolysis in stroke: it works! BMJ, March 23, 2002; 324(7339): 723 - 729. [Full Text] [PDF]

				G. W. Albers, W. M. Clark, K. P. Madden, S. A. Hamilton, S. M. Davis, and G. A. Donnan ATLANTIS Trial: Results for Patients Treated Within 3 Hours of Stroke Onset * Editorial Comment: Results for Patients Treated Within 3 Hours of Stroke Onset Stroke, February 1, 2002; 33(2): 493 - 496. [Abstract] [Full Text] [PDF]

				J. R. Toomey, R. E. Valocik, P. F. Koster, M. A. Gabriel, M. McVey, T. K. Hart, E. H. Ohlstein, A. A. Parsons, and F. C. Barone Inhibition of Factor IX(a) Is Protective in a Rat Model of Thromboembolic Stroke Stroke, February 1, 2002; 33(2): 578 - 585. [Abstract] [Full Text] [PDF]

				S. Ishikawa, K. Yokoyama, T. Kuroiwa, and K. Makita Evolution of cerebral ischaemia induced by thromboembolism in rats detected by early sequential MR imaging Br. J. Anaesth., September 1, 2001; 87(3): 469 - 476. [Abstract] [Full Text] [PDF]

				C. A. Molina, J. Montaner, S. Abilleira, B. Ibarra, F. Romero, J. F. Arenillas, and J. Alvarez-Sabin Timing of Spontaneous Recanalization and Risk of Hemorrhagic Transformation in Acute Cardioembolic Stroke Stroke, May 1, 2001; 32(5): 1079 - 1084. [Abstract] [Full Text] [PDF]

				K. Uchino, D. Billheimer, and S. C. Cramer Entry Criteria and Baseline Characteristics Predict Outcome in Acute Stroke Trials Stroke, April 1, 2001; 32(4): 909 - 916. [Abstract] [Full Text] [PDF]

				V. Keris, S. Rudnicka, V. Vorona, G. Enina, B. Tilgale, and J. Fricbergs Combined Intraarterial/Intravenous Thrombolysis for Acute Ischemic Stroke AJNR Am. J. Neuroradiol., February 1, 2001; 22(2): 352 - 358. [Abstract] [Full Text] [PDF]

				H. B. van der Worp, S. P. Claus, P. R. Bar, L. M. P. Ramos, A. Algra, J. van Gijn, and L. J. Kappelle Reproducibility of Measurements of Cerebral Infarct Volume on CT Scans Stroke, February 1, 2001; 32(2): 424 - 430. [Abstract] [Full Text] [PDF]

				G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Chest, January 1, 2001; 119(1_suppl): 300S - 320S. [Full Text] [PDF]

				R. von Kummer, S. C. Jones, T. A. Kent, and D. K. Kim The Time Concept in Ischemic Stroke: Misleading Response Stroke, October 1, 2000; 31 (10): 2517 - 2527. [Full Text] [PDF]